Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 3/20 | 0.46 |
| ▸ | TGM2 | P21980 | 3/20 | 0.46 |
| ▸ | TGM1 | P22735 | 3/20 | 0.46 |
| ▸ | SFRP1 | Q8N474 | 11/20 | 0.45 |
| ▸ | WNT3 | P56703 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24762619 | 0.84 | HTR2A (0.45) | KDM1AMCL1BCL2A1 | |
| SCHEMBL24763408 | 0.83 | KDM1A (0.47) | KDM1A | |
| SCHEMBL24762182 | 0.80 | PKM (0.55) | — | |
| SCHEMBL24762715 | 0.79 | CA12 (0.37) | THRBKDM1AMCL1BCL2A1 | |
| SCHEMBL24762679 | 0.78 | MEN1 (0.46) | HTTSFRP1KDM1A | |
| SCHEMBL24762021 | 0.78 | MAPK1 (0.56) | HTTKDM1A | |
| SCHEMBL27238545 | 0.77 | CA12 (0.41) | — | |
| SCHEMBL24762140 | 0.77 | HTT (0.47) | HTTTHRBMCL1BCL2A1 | |
| SCHEMBL27238539 | 0.74 | PKM (0.40) | — | |
| SCHEMBL27238639 | 0.73 | ALDH1A1 (0.36) | HTTTHRBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | HTT 2866/4885F13A1 2838/4885TGM2 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.